Reduced Episignature Classifier for Sotos Syndrome as a Supporting Diagnostic and Research Tool
Current Issues in Molecular Biology · 20.11.2026 · 48 (11) · 1254
DOI: 10.3390/cimb48111254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 20.11.2026. Verfasst von Anna V. Efremova und 10 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation for Research Centre for Medical Genetics.
Abstract (Originalsprache)
Sotos syndrome, an autosomal dominant neurodevelopmental disorder caused by pathogenic variants in the NSD1 gene, exhibits a distinct genome-wide DNA methylation episignature characterized by widespread hypomethylation. While genome-wide methylation signatures provide robust diagnostic accuracy, their implementation in routine clinical practice is limited by cost and technical complexity. This study aimed to reduce the Sotos syndrome episignature to a confined set of CpG sites intended for Sanger bisulfite sequencing. We selected four loci containing CpG dinucleotides with the most significant methylation changes based on published data. Bisulfite Sanger sequencing was performed on patients with the molecularly confirmed Sotos syndrome and healthy controls. The obtained methylation levels of the analyzed loci were then used as features to build a binary classification model using machine learning methods. We employed the Random Forest-based method to conduct a feature selection, which identified two CpG sites (chr6:28601375 and chr6:28601440) as the most important predictors. A logistic regression classification model was developed using selected CpG sites. The resulting two-predictor model demonstrated excellent performance and achieved 100% accuracy on the held-out test set. All Sotos syndrome samples were classified correctly, while Malan syndrome samples showed methylation levels comparable to controls. Two samples with VUS in the NSD1 gene were classified together with all samples with pathogenic NSD1 variants. For these two cases, we performed a de novo assessment of the variant status and reclassified the variants (NSD1(NM_022455.5): c.6523T>C and c.8005del, respectively) into likely pathogenic, confirming the validity of the results of the reduced episignature analysis. Thus, our cost-effective approach can potentially serve as a supporting diagnostic and research tool, particularly for variant reclassification and differential diagnosis in resource-limited settings.
Förderung
- Ministry of Science and Higher Education of the Russian Federation for Research Centre for Medical Genetics
Zitieren
APA
Efremova, A. V., Zemlianaia, O. A., Kalinkin, A. I., Volodin, I. V., Semenova, N. A., Smirnov, A. S., Tanas, A. S., Zaletaev, D. V., Nemtsova, M. V., Kutsev, S. I., & Strelnikov, V. V. (2026). Reduced Episignature Classifier for Sotos Syndrome as a Supporting Diagnostic and Research Tool. Current Issues in Molecular Biology, 48(11), 1254. https://doi.org/10.3390/cimb48111254
Vancouver
Efremova AV, Zemlianaia OA, Kalinkin AI, Volodin IV, Semenova NA, Smirnov AS, et al. Reduced Episignature Classifier for Sotos Syndrome as a Supporting Diagnostic and Research Tool. Current Issues in Molecular Biology. 2026;48(11):1254. doi:10.3390/cimb48111254
BibTeX
@article{Efremova2026,
author = {Efremova, Anna V. and Zemlianaia, Olga A. and Kalinkin, Alexey I. and Volodin, Ilya V. and Semenova, Natalia A. and Smirnov, Anton S. and Tanas, Alexander S. and Zaletaev, Dmitry V. and Nemtsova, Marina V. and Kutsev, Sergey I. and Strelnikov, Vladimir V.},
title = {Reduced Episignature Classifier for Sotos Syndrome as a Supporting Diagnostic and Research Tool},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {11},
pages = {1254},
doi = {10.3390/cimb48111254}
}
EUVIMED